The clusters were: “#1 certolizumab pegol”, “#2 therapeutic drug monitoring”, “#3 intestinal inflammation”, “#4 fecal microbiota transplantation”, “#5 JAK inhibitor”, “#6 real-world effectiveness”, “#7 intestinal ultrasound”, “#8 Crohn’s disease”, “#9 rheumatoid arthritis”, “#10 toll-like receptor”, “#11 exclusive enteral nutrition”, “#12 perianal fistula”, “#13 thiopurine methyltransferase”, “#14 enteric microflora”, “#15 pediatric inflammatory bowel disease”, “#16 pregnant patient”, “#17 postoperative outcome”, “#18 fistulizing Crohn’s disease”, and “#19 position statement”. This evidence concerns the gene TPMT and Crohn disease.